Table 1 Characteristics of the studies included in the analysis of the incidence of AKI in hospitalized COVID-19 patients
Study | Year | Country | Design | Sample size | Age (median/ mean) | Male (%) | The diagnosis criteria of AKI | Department | Quality score |
|---|---|---|---|---|---|---|---|---|---|
Yichun Cheng [6] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 701 | 63 | 52.4% | 2012 KDIGO criteria Stage 1(n = 13) Stage 2 (n = 9) Stage 3(n = 14) | Hospitalized Patients | AHRQ 8 |
Weijie Guan [13] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 1099 | 47 | 58.1% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 9 |
Chaolin Huang [14] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 41 | 49 | 73.0% | 2012 KDIGO criteria CRRT 3(7%) | Hospitalized Patients | AHRQ 8 |
Shaobo Shi [15] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 416 | 64 | 49.7% | 2012 KDIGO criteria CRRT 2(0.5%) | Hospitalized Patients | AHRQ 9 |
Luwen Wang [16] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 116 | 54 | 57.8% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 6 |
Dawei Wang [17] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 138 | 56 | 54.3% | 2012 KDIGO criteria CRRT 2(1.45%) | Hospitalized Patients | AHRQ 8 |
Fei Zhou [18] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 191 | 56 | 62.0% | 2012 KDIGO criteria CRRT 10(5%) | Hospitalized Patients | AHRQ 8 |
Dawei Wang [19] | 2020 | China, Wuhan and Huanggang | Retrospective Cross-sectional study | 107 | 51 | 53.3% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 7 |
Tao Chen [20] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 274 | 62.0 | 62.4% | 2012 KDIGO criteria CRRT 3(1%) | Hospitalized Patients | AHRQ 8 |
Xiaochen Li [21] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 548 | 60 | 50.9% | 2012 KDIGO criteria CRRT 2(0.4%) | Hospitalized Patients | AHRQ 8 |
Xiaobo Yang [22] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 52 | 51.9 | 70% | 2012 KDIGO criteria CRRT 9(17%) | ICU Patients | AHRQ 7 |
Yuan Yu [23] | 2020 | China, Wuhan | Retrospective Cross-sectional study | 226 | 64 | 61.5% | 2012 KDIGO criteria Stage 1 (n = 23); Stage2 (n = 12); Stage 3 (n = 22) | ICU Patients | AHRQ 7 |
KyungSoo Hong [24] | 2020 | Korea, Daegu | Retrospective Cross-sectional study | 98 | 55.4 | 38.8% | 2012 KDIGO criteria CRRT 3(3.1%) | Hospitalized Patients | AHRQ 6 |
Safiya Richardson [25] | 2020 | USA, New York | Retrospective Cross-sectional study | 5700 | 63 | 60.3% | 2012 KDIGO criteria CRRT 81(3.2%) | Hospitalized Patients | AHRQ 8 |
Jamie S. Hirsch [5] | 2020 | USA, New York | Retrospective Cross-sectional study | 5449 | 64.0 | 60.9% | 2012 KDIGO criteria CRRT 285(5.2%) | Hospitalized Patients | AHRQ 8 |
Jessica Ferguson [26] | 2020 | USA, California | Retrospective Cross-sectional study | 72 | 60.4 | 52.8% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 6 |
Matt Arentz [27] | 2020 | USA, Washington | Retrospective Cross-sectional study | 21 | 79 | 52% | 2012 KDIGO criteria | ICU Patients | AHRQ 8 |
J.H. Beigel [28] | 2020 | United States, Denmark, the United Kingdom,Greece, Germany, Korea, Mexico, Spain, Japan, and Singapore | RCT (Remdesivir) | 1062 | 58.9 | 64.3% | 2012 KDIGO criteria | Hospitalized Patients | Cochrane A |
Spinello Antinori [29] | 2020 | Italy, Milan | Prospective, Cross-sectional study (Remdesivir) | 35 | 63.0 | 74.3% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 6 |
J. Grein [30] | 2020 | United States, Japan, Italy, Austria, France, Germany, Netherlands, Spain, and Canada | Prospective, Cross-sectional study (Remdesivir) | 53 | 64 | 75% | 2012 KDIGO criteria | Hospitalized Patients | AHRQ 8 |
Yeming Wang [31] | 2020 | China, Wuhan | RCT (Remdesivir) | 236 | 66.0 | 56% | 2012 KDIGO criteria | Hospitalized Patients | Cochrane A |
Jason D. Goldman [32] | 2020 | United States, Italy, Spain, Germany, Hong Kong, Singapore, South Korea, and Taiwan | RCT (Remdesivir) | 397 | 62 | 64% | 2012 KDIGO criteria | Hospitalized Patients | Cochrane A |